Impacted: Clients using ESI in 2024/2025

What you need to know
Effective February 1, 2025: Express Scripts (ESI) will resume dispensing glucagon-like peptide-1 (GLP-1) drugs to new-to-therapy (NTT) members through the ESI Home Delivery pharmacy. This change applies to all GLP-1 medications, whether prescribed for weight loss or diabetes.

Overview
As previously communicated, Prime Therapeutics (Prime) was informed by ESI that starting December 1, 2024, they would not dispense GLP-1 drugs to NTT members. This measure ensured current users maintained access during anticipated January 2025 shortages. The block only affected injectable GLP-1 drugs, as oral versions had no historical supply issues. After reevaluation, ESI decided to lift the block without risking access for existing therapy members.

Questions?
Please reach out to your account representative if you have questions.